Get started
Author

Thomas Sandal

Observed name: T. Sandal
ORCID: 0000-0002-4273-0234
Observed ORCID: 0000-0002-4273-0234
OpenAlex ID: A5073267109
Comparison of expression systems in the yeasts Saccharomyces cerevisiae, Hansenula polymorpha, Klyveromyces lactis, Schizosaccharomyces pombe and Yarrowia lipolytica. cloning of two novel promoters from Yarrowia lipolytica
1998 · Sven Müller, Thomas Sandal, et al. · Yeast · 251
Increased Tumor Penetration of Single-Domain Antibody–Drug Conjugates Improves In Vivo Efficacy in Prostate Cancer Models
2020 · Ian Nessler, Eshita Khera, et al. · Cancer Research · 133
Expression cloning, purification and characterization of a β-1,4-glactanase from Aspergillus aculeatus
1995 · Stephan Christgau, Thomas Sandal, et al. · Current Genetics · 55
Diverse human VH antibody fragments with bio-therapeutic properties from the Crescendo Mouse
2019 · Yumin Teng, Joyce L. Young, et al. · New Biotechnology · 30
PDF
Cloning and characterization of an endo-β-1,3(4)glucanase and an aspartic protease from Phaffia rhodozyma CBS 6938
1999 · M. L. Bang, I. Villadsen, et al. · Applied Microbiology and Biotechnology · 30
Discovery and Preclinical Characterization of a Novel Hepcidin Antagonist with Tunable PK/PD Properties for the Treatment of Anemia in Different Patient Populations
2011 · Andreas M Hohlbaum, Stefan Trentman, et al. · Blood · 16
Crystallization and preliminary X-ray studies of β-1,4-galactanase from Aspergillus aculeatus
1999 · C. Ryttersgaard, J.-C. N. Poulsen, et al. · Acta Crystallographica Section D Biological Crystallography · 5
2D-PAGE examination of mRNA populations from Pénicillium freii mutants deficient in xanthomegnin biosynthesis
1996 · Mogens Nicolaisen, Thomas Sandal, et al. · Microbiological Research · 4
Crystallization and preliminary X-ray studies of β-1,4-galactanase from Aspergillus aculeatus
1999 · C. Ryttersgaard, J. C. N. Poulsen, et al. · Acta Crystallographica Section D Biological Crystallography · 3
Data from Tri-Specific Humabody CB307 Targeting CD137, Prostate-Specific Membrane Antigen, and Human Serum Albumin Whole-Body Biodistribution Measured with 89Zr-CB307 PET
2026 · Daan G. Knapen, Claudia A.J. van Winkel, et al.
Figure S3 from Tri-Specific Humabody CB307 Targeting CD137, Prostate-Specific Membrane Antigen, and Human Serum Albumin Whole-Body Biodistribution Measured with 89Zr-CB307 PET
2026 · Daan G. Knapen, Claudia A.J. van Winkel, et al.
Figure S1 from Tri-Specific Humabody CB307 Targeting CD137, Prostate-Specific Membrane Antigen, and Human Serum Albumin Whole-Body Biodistribution Measured with 89Zr-CB307 PET
2026 · Daan G. Knapen, Claudia A.J. van Winkel, et al.
Figure S2 from Tri-Specific Humabody CB307 Targeting CD137, Prostate-Specific Membrane Antigen, and Human Serum Albumin Whole-Body Biodistribution Measured with 89Zr-CB307 PET
2026 · Daan G. Knapen, Claudia A.J. van Winkel, et al.
Figure S7 from Tri-Specific Humabody CB307 Targeting CD137, Prostate-Specific Membrane Antigen, and Human Serum Albumin Whole-Body Biodistribution Measured with 89Zr-CB307 PET
2026 · Daan G. Knapen, Claudia A.J. van Winkel, et al.
Figure S6 from Tri-Specific Humabody CB307 Targeting CD137, Prostate-Specific Membrane Antigen, and Human Serum Albumin Whole-Body Biodistribution Measured with 89Zr-CB307 PET
2026 · Daan G. Knapen, Claudia A.J. van Winkel, et al.
Figure S4 from Tri-Specific Humabody CB307 Targeting CD137, Prostate-Specific Membrane Antigen, and Human Serum Albumin Whole-Body Biodistribution Measured with 89Zr-CB307 PET
2026 · Daan G. Knapen, Claudia A.J. van Winkel, et al.
Figure S5 from Tri-Specific Humabody CB307 Targeting CD137, Prostate-Specific Membrane Antigen, and Human Serum Albumin Whole-Body Biodistribution Measured with 89Zr-CB307 PET
2026 · Daan G. Knapen, Claudia A.J. van Winkel, et al.
Supplementary Methods from Tri-Specific Humabody CB307 Targeting CD137, Prostate-Specific Membrane Antigen, and Human Serum Albumin Whole-Body Biodistribution Measured with 89Zr-CB307 PET
2026 · Daan G. Knapen, Claudia A.J. van Winkel, et al.
Figure S8 from Tri-Specific Humabody CB307 Targeting CD137, Prostate-Specific Membrane Antigen, and Human Serum Albumin Whole-Body Biodistribution Measured with 89Zr-CB307 PET
2026 · Daan G. Knapen, Claudia A.J. van Winkel, et al.
Tri-Specific Humabody CB307 Targeting CD137, Prostate-Specific Membrane Antigen, and Human Serum Albumin Whole-Body Biodistribution Measured with 89Zr-CB307 PET
2026 · Daan G. Knapen, Claudia A.J. van Winkel, et al. · Molecular Cancer Therapeutics
Data from Increased Tumor Penetration of Single-Domain Antibody–Drug Conjugates Improves In Vivo Efficacy in Prostate Cancer Models
2023 · Ian Nessler, Eshita Khera, et al.
Supplementary Data from Increased Tumor Penetration of Single-Domain Antibody–Drug Conjugates Improves In Vivo Efficacy in Prostate Cancer Models
2023 · Ian Nessler, Eshita Khera, et al.
Supplementary Data from Increased Tumor Penetration of Single-Domain Antibody–Drug Conjugates Improves In Vivo Efficacy in Prostate Cancer Models
2023 · Ian Nessler, Eshita Khera, et al.
Works count: 23
Citation count: 527
H-index: 6
I10-index: 6
Year
Topic
Type